References
- N. Koseki, H. Kawashita, H. Hara, M. Niina, M. Tanaka, R. Kawai, Y. Nagae and N. Masuda, Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry, J. Pharm. Biomed. Anal. 43 (2007) 1769-1774; DOI: 10.1016/j.jpba.2006.12.030.
- M. Doménech and A. Coca, Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure, Patient Pref. Adh. 4 (2010) 105-113.
- The Merck Index (Ed. S. Budavari), 13th ed. Merck & Co. Inc., Whitehouse Station (NJ) 2001.
- N. Daneshtalab, R. Z. Lewanczuk and F. Jamali, High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method, J. Chromatogr. B. 766 (2002) 345-349; DOI: 10.1016/S0378-4347(01)00507-2.
- E. K. Schmidt, K. H. Antonin, G. Flesch and A. Racine-Poon, An interaction study with cimetidine and the new angiotensin II antagonist valsartan, Eur. J. Clin. Pharmacol. 53 (1998) 451-458; DOI: 10.1007/s002280050406.
- F. Waldmeier, G. Flesch, P. Muller, T. Winkler, H. P. Kriemler, P. Buhlmayer and M. De Gasparo, Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose, Xenobiotica 27 (1997) 59-71; DOI: 10.1080/004982597240767.
- P. Pickkers, A. D. Hughes, F. G. M. Russel, T. Thien and P. Smits, Thiazide-induced vasodilation in humans is mediated by potassium channel activation, Hypertension 32 (1998) 1071-1076.
- S. G. Chrysant, Fixed low-dose drug combination for the treatment of hypertension, Arch. Fam. Med. 7 (1998) 370-376; DOI: 10.1001/archfami.7.4.370.
- J. Macek, J. Klima and P. Ptácek, Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography, J. Chromatogr. B 832 (2006) 169-172; DOI: 10.1016/j.jchromb.2005.12.035.
- B. Koçyiğit-Kaymakçoğlu, S. Unsalan and S. Rollas, Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography, Pharmazie 61 (2006) 586-589.
- Zarghi, S. M. Foroutan, A. Shafaati and A. Khoddam, Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies, Farmaco 60 (2005) 789-792; DOI: 10.1016/j.farmac.2005.06.012.
- R. V. S. Nirogi, V. N. Kandikere, K. Mudigonda, M. Shukla and S. Maurya, Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma, Biomed. Chromatogr. 20 (2006) 833-842; DOI: 10.1002/bmc.600.
- L. Li, J. Sun, P. Yang and Z. He, Liquid chromatography-electrospray ionization mass spectrometric method for the determination of hydrochlorothiazide in human plasma: application to a pharmacokinetic study, Anal. Lett. 39 (2006) 2797-2807; DOI: 10.1080/00032710600867465.
- H. Li, Y. Wang, Y. Jiang, Y. Tang, J. Wang, L. Zhao and J. Gu, A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma, J. Chromatog. B 852 (2007) 436-442; DOI: 10.1016/j.jchromb.2007.02.014.
- M. Çelebier, M. S. Kaynak, S. Altınöz and S. Şahin, Validated HPLC method development: the simultaneous analysis of amlodipine and valsartan in samples for liver perfusion studies, Hacettepe Univ. J. Fac. Phar. 28 (2008) 15-30.
- FDA, Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, FDA, CDER and CVM, Rockville 2001.
- EMEA, Draft Guidelines on Validation of Bioanalytical Methods, Committee for Medicinal Products for Human Use, EMEA, London 2009.